Name | Gap19 |
---|
Description | Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial[1][2]. |
---|---|
Related Catalog | |
Target |
Cx43 Hemichannel[1] |
In Vitro | Gap19 (250 μM; for 30 min ) decreases mitochondrial potassium uptake[1]. Gap19 (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells[2]. Gap19 (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes[2]. Gap19 (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo[2]. |
In Vivo | Gap19 (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth[2]. Animal Model: C57/BL6 mice[2] Dosage: 25 mg/kg Administration: IV; 10 min before ligation Result: Significantly reduced the infarct size by approximately one-fifth. |
References |
Molecular Formula | C55H96N14O13 |
---|---|
Molecular Weight | 1161.44 |
Storage condition | -20°C |